| HOME >> BIOLOGY >> TECHNOLOGY |
NANJING, China, Nov. 6 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical
Group ("Simcere" or the "Company') (NYSE: SCR), a leading manufacturer and
supplier of branded generic pharmaceuticals and manufacturer of the
patented anti- cancer biotech product Endu in China, today reported
unaudited financial results for the quarter ended September 30, 2008 and
announced that its Board of Directors has approved a share repurchase
program.
Highlights
-- Total revenue increased to RMB443.4 million (US$65.3 million) for the
third quarter, representing a 37.1% year-over-year growth;
-- Net income was RMB91.2 million (US$13.4 million) for the third quarter,
representing a 24.7% year-over-year growth;
-- Gross margin was 78.3% for the third quarter, which was impacted by a
one-off contract sale transaction involving the resale of generic drugs
for other pharmaceutical companies, which is now ceased; and
-- The board of directors has approved a share repurchase program under
which Simcere Pharmaceutical Group may purchase up to US$50 million
worth of its issued and outstanding American depositary shares
("ADSs") in the following twelve months.
Mr. Jinsheng Ren, Chairman and CEO of Simcere Pharmaceutical Group,
commented: "We are pleased to report solid year on year growth for the
third quarter. We are encouraged by the continued growth of our edaravone
products, although our Endu sales continued to be affected by the sales
team restructuring and an expanded program to supply Endu free of charge in
clinical studies. Our other branded generic products grew steadily this
quarter. In October, we successfully launched Anxin, our first-to-market
biapenem
'/>"/>
| SOURCE Simcere Pharmaceutical Group Copyright©2008 PR Newswire. All rights reserved |